Intec Pharma (NASDAQ:NTEC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Monday. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 146.15% from the stock’s current price.
A number of other brokerages have also recently issued reports on NTEC. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Ladenburg Thalmann Financial Services began coverage on shares of Intec Pharma in a report on Wednesday, February 28th. They issued a “buy” rating for the company. Maxim Group set a $8.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a report on Friday, November 17th. Finally, ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $12.00.
Intec Pharma (NASDAQ:NTEC) opened at $6.50 on Monday. Intec Pharma has a fifty-two week low of $4.80 and a fifty-two week high of $9.80.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.